Can Pharma Companies Expand the Current Ankylosing Spondylitis (AS) Market with a New Indication


August 1, 2017 (STL.News) According to the surveyed physicians, biologic agents are prescribed in just over half of the AS patients under their management but in a significantly lower proportion of their nr-axSpA patients.  The specific biologic brands prescribed, however, do not differ significantly in terms of share between AS and nr-axSpA, with AbbVie s Humira [ ] The post Can Pharma Companies Expand the Current Ankylosing Spondylitis (AS) Market with a New Indication appeared first on STL News.
http://bit.ly/2ufItqD

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Create a website or blog at WordPress.com

Up ↑

%d bloggers like this: